Otsuka and Jiangsu HengRui Medicine side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Otsuka | Jiangsu HengRui Medicine |
|---|---|---|
| Phase 1 | Otsuka: 12 of its 25 programs at phase 1
and 7 more — sign in to see them all | Jiangsu HengRui Medicine: 52 of its 155 programs at phase 1
and 47 more — sign in to see them all |
| Phase 2 | Otsuka: 2 of its 25 programs at phase 2
| Jiangsu HengRui Medicine: 50 of its 155 programs at phase 2 and 45 more — sign in to see them all |
| Phase 3 | Otsuka: 10 of its 25 programs at phase 3
and 5 more — sign in to see them all | Jiangsu HengRui Medicine: 51 of its 155 programs at phase 3
and 46 more — sign in to see them all |
| Approved, new studies | Otsuka: 1 of its 25 programs at approved, new studies
| Jiangsu HengRui Medicine: 2 of its 155 programs at approved, new studies
|
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Otsuka8 readouts · 3 phase 3 | · | Otsuka, Dec ’26: 2 programs whose next study reaches primary completion, 1 in phase 3
| · | Otsuka, Feb ’27: 1 program whose next study reaches primary completion
| Otsuka, Mar ’27: 1 program whose next study reaches primary completion
| · | Otsuka, May ’27: 2 programs whose next study reaches primary completion, 2 in phase 3
| Otsuka, Jun ’27: 1 program whose next study reaches primary completion
| · | Otsuka, Aug ’27: 1 program whose next study reaches primary completion | · | · |
| Jiangsu HengRui Medicine75 readouts · 11 phase 3 | Jiangsu HengRui Medicine, Nov ’26: 2 programs whose next study reaches primary completion
| Jiangsu HengRui Medicine, Dec ’26: 32 programs whose next study reaches primary completion, 4 in phase 3
and 27 more — sign in to see them all | Jiangsu HengRui Medicine, Jan ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Jiangsu HengRui Medicine, Feb ’27: 8 programs whose next study reaches primary completion
and 3 more — sign in to see them all | Jiangsu HengRui Medicine, Mar ’27: 8 programs whose next study reaches primary completion, 3 in phase 3
and 3 more — sign in to see them all | Jiangsu HengRui Medicine, Apr ’27: 6 programs whose next study reaches primary completion
and 1 more — sign in to see them all | Jiangsu HengRui Medicine, May ’27: 1 program whose next study reaches primary completion
| Jiangsu HengRui Medicine, Jun ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Jiangsu HengRui Medicine, Jul ’27: 5 programs whose next study reaches primary completion
| · | Jiangsu HengRui Medicine, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Jiangsu HengRui Medicine, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
|
Changed in the last 90 days
Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Otsuka
New programs 0
None
Reached a new phase 1
- VIS954phase 2 · Oct 23 · Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Study stopped 1
- SEP-380135phase 1 · withdrawn Nov 19 · none of its studies left running“The trial was withdrawn prior to participant enrollment.” · NCT07455084
Primary completion later 3
- quabodepistatphase 3 · May 2027 → Sep 2028 (+16 mo) · moved Oct 26 · NCT07209761
- Tolvaptanphase 3 · Jul 2028 → Dec 2028 (+5 mo) · moved Oct 23 · NCT04782258
- SEP-380135phase 1 · Apr 2026 → Dec 2026 (+8 mo) · moved Oct 16 · NCT07455084
Jiangsu HengRui Medicine
New programs 11
- HRS-9308 Tabletphase 2 · first study · Nov 11
- HRS-8046 Tabletphase 1 · first study · Nov 6
- SHR 3201phase 1 · first study · Oct 16 · Alzheimer Disease
- RLX-2508early phase 1 · first study · Oct 8 · Influenza, Human
- adebeliizumab + SHR-A2009phase 2 · first study · Sep 30 · Carcinoma, Non-Small-Cell Lung
- HR19034phase 3 · first study · Sep 22 · Myopia
Jiangsu HengRui Medicine: new programs in 90 days
- HRS-9308 Tabletphase 2 · first study · Nov 11
- HRS-8046 Tabletphase 1 · first study · Nov 6
- SHR 3201phase 1 · first study · Oct 16
- RLX-2508early phase 1 · first study · Oct 8
- adebeliizumab + SHR-A2009phase 2 · first study · Sep 30
and 6 more — sign in to see them all
Reached a new phase 4
- SHR-3167phase 3 · Oct 28 · Diabetes Mellitus, Type 2
- HRS-6209phase 3 · Oct 14 · Breast Neoplasms
- HRS-7172phase 2 · Sep 2 · Lung Neoplasms
- FH-006phase 3 · Aug 25 · Lung Neoplasms
Study stopped 0
None
Primary completion later 6
- SHR-7590phase 1 · Jan 2027 → Mar 2028 (+14 mo) · moved Nov 17 · NCT07758101
- adebrelimabphase 3 · Apr 2031 → Sep 2031 (+5 mo) · moved Oct 29 · NCT07691762
- Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Apr 2031 → Sep 2031 (+5 mo) · moved Oct 29 · NCT07691762
- HRS-8080phase 3 · Dec 2026 → Aug 2027 (+8 mo) · moved Oct 2 · NCT07024173
- HRS-8427phase 2 · Feb 2026 → Sep 2026 (+7 mo) · moved Sep 30 · NCT06841731
- Anti-CTLA-4 Monoclonal Antibody SHR-8068phase 3 · Sep 2026 → Oct 2026 (+1 mo) · moved Sep 25 · NCT06618664
Where they overlap
Conditions where at least two of them have programs: 15 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Otsuka | Jiangsu HengRui Medicine |
|---|---|---|
| EGFR | zipalertinibrule | aumolertinibrule |
| PDCD1 | zimberelimabrule | SHR-3045 |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Jiangsu HengRui Medicine: 1).